BMS-955176: Difference between revisions
No edit summary |
m Moving from Category:Experimental drugs to Category:Experimental antiviral drugs using Cat-a-lot |
||
(17 intermediate revisions by 15 users not shown) | |||
Line 1:
{{Short description|Chemical compound}}
{{Infobox drug
| drug_name =
| INN =
| type =<!-- empty -->
| IUPAC_name =
| image = BMS-955176.svg
| alt =
| caption =
<!-- Clinical data -->
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment =
| pregnancy_US = <!-- A/B/C/D/X/N -->
| pregnancy_category=
| routes_of_administration =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
Line 27 ⟶ 28:
| legal_status = Investigational
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
<!-- Identifiers -->
| CAS_number = 1392312-45-6
| UNII_Ref = {{fdacite|correct|FDA}}
| ATCvet = ▼
| UNII = 4CA9IAU7RJ
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix =
| PubChem =
|
| DrugBank =
<!-- Chemical data -->
| C=42|H=62|N=2|O=4|S=1
| molecular_weight =
| smiles = CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)c6ccc(cc6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
| StdInChI = 1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1
| StdInChIKey = XDMUFNNPLXHNKA-ZTESCHFWSA-N
}}
'''BMS-955176''' is an experimental second generation [[HIV]] [[maturation inhibitor]] under [[drug development|development]] by [[Bristol-Myers Squibb]] for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.<ref>
__TOC__
== Studies ==
Results of a [[Clinical trial|phase 2a]] trial of BMS-955176 was reported at the 2015 [[Conference on Retroviruses and Opportunistic Infections]] (CROI).<ref name=":0">{{Cite web|title = Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor {{!}} CROI Conference|url = http://www.croiconference.org/sessions/antiviral-activitysafety-second-generation-hiv-1-maturation-inhibitor|website = www.croiconference.org|
It appears that development of BMS-955176 has been terminated.<ref>{{cite web|url=http://www.thebodypro.com/content/78689/gsk-discontinues-development-of-maturation-inhibit.html|title=GSK Discontinues Development of Maturation Inhibitor BMS-955176}}</ref>
== See also ==
* [[Fipravirimat]]
== References ==
{{reflist}}
Line 59 ⟶ 71:
[[Category:Antiretroviral drugs]]
[[Category:Maturation inhibitors]]
[[Category:Experimental antiviral drugs]]
|
Latest revision as of 20:41, 1 December 2023
Legal status | |
---|---|
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C42H62N2O4S |
Molar mass | 691.03 g·mol−1 |
3D model (JSmol) | |
| |
|
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]
Studies
[edit]Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5]
It appears that development of BMS-955176 has been terminated.[6]
See also
[edit]References
[edit]- ^ "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. Archived from the original on 23 July 2015. Retrieved 22 July 2015.
- ^ "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform".
- ^ Wang D, Lu W, Li F (November 2015). "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica B. 5 (6): 493–9. doi:10.1016/j.apsb.2015.05.004. PMC 4675807. PMID 26713265.
- ^ a b "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". www.croiconference.org. Retrieved 2016-01-01.
- ^ "HIV maturation inhibitor BMS-955176 looks promising in early study". www.aidsmap.com. Retrieved 2016-01-01.
- ^ "GSK Discontinues Development of Maturation Inhibitor BMS-955176".